A61K 2239/28
Expressing multiple cars, tcrs or antigens
Official title: Expressing multiple CARs, TCRs or antigens
A61K2239/28 (Expressing multiple cars, tcrs or antigens) appears on 109 US grants and 399 published applications in this corpus.
Search patents in A61K- Granted patents
- 109
- Published applications
- 399
- Assignees
- 193
- Inventors
- 1,004
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 3 |
| 2016 | 0 | 4 |
| 2017 | 3 | 4 |
| 2018 | 0 | 18 |
| 2019 | 5 | 14 |
| 2020 | 5 | 29 |
| 2021 | 5 | 39 |
| 2022 | 11 | 51 |
| 2023 | 18 | 41 |
| 2024 | 28 | 103 |
| 2025 | 14 | 47 |
| 2026 | 19 | 43 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Humanized CD19 antibody and use thereof15 Sep 2026US 12,735,482 B2Gracell Bioscience (Shanghai) Co., Ltd.
- Molecular engineering to enhance CAR-T mediated tumor immunotherapy1 Sep 2026US 12,721,891 B2Hackensack Meridian Health, Inc.
- Presenting cell and use thereof in cell therapy11 Aug 2026US 12,702,708 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Switch receptors1 Oct 2026US 2026/0295042 A1Hoffmann-La Roche Inc.
- Viral vectors for glioblastoma cell therapy24 Sep 2026US 2026/0284109 A1
- Coreceptor chimeric antigen receptor24 Sep 2026US 2026/0284111 A1
- Il-9r signaling compositions and methods10 Sep 2026US 2026/0263516 A1The Regents of the University of California
- Compositions and methods for cellular immunotherapy27 Aug 2026US 2026/0250405 A1Fred Hutchinson Cancer Center
Most cited
By later US patents
- Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy108US 9,745,368 B2Novartis AG · 2017
- Activated dual specificity lymphocytes and their methods of use32US 7,723,111 B2The United States of America as represented by the Department of Health and Human Services · 2010
- Peptidic chimeric antigen receptor T cell switches and uses thereof21US 9,624,276 B2The California Institute for Biomedical Research · 2017
- Cell19US 10,172,885 B2UCL Business PLC · 2019
- Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof18US 9,777,064 B2Chimera Bioengineering, Inc. · 2017